Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Vaccine

• Publication date

  2013-11-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2013.06.049PMID 24004465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations: Immunogenicity and Safety

  2012cited by this paper
• Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.

  2011cited by this paper
• Epidemiology of pediatric community-acquired bloodstream infections in a children hospital in Paris, France, 2001 to 2008.

  2010cited by this paper
• Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

  2010cited by this paper
• Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.

  2010cited by this paper
• Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.

  2010cited by this paper
• Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.

  2010cited by this paper
• Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

  2010cited by this paper
• Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain.

  2009cited by this paper
• Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants.

  2009cited by this paper
• Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine

  2009cited by this paper
• Changes in serotypes causing invasive pneumococcal disease (2005-2007 vs. 1997-1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine.

  2009cited by this paper
• Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Different Neisseria meningitidis Serogroup C Conjugate Vaccines

  2009cited by this paper
• Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona.

  2009cited by this paper
• Immunogenicity of Routinely Used Childhood Vaccines When Coadministered With the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV)

  2009cited by this paper
• Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.

  2009cited by this paper
• Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology.

  2009cited by this paper
• Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

  2008cited by this paper
• Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.

  2008cited by this paper
• EPSTEIN-BARR VIRUS LOAD IN CEREBROSPINAL FLUID OF PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION

  2008cited by this paper
• Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine.

  2008cited by this paper
• Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.

  2006cited by this paper
• Burden of paediatric invasive pneumococcal disease in Europe, 2005

  2006cited by this paper
• Immunogenicity and Safety of Measles-Mumps-Rubella, Varicella and Haemophilus influenzae Type b Vaccines Administered Concurrently With a Fourth Dose of Heptavalent Pneumococcal Conjugate Vaccine Compared With the Vaccines Administered Without Heptavalent Pneumococcal Conjugate Vaccine

  2006cited by this paper
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.

  2005cited by this paper
• Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial.

  2005cited by this paper
• Immunogenicity and Tolerability of a Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 12 Months of Age

  2005cited by this paper
• Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona

  2004cited by this paper
• Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides

  2003cited by this paper
• Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

  2003cited by this paper
• Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England

  2003cited by this paper
• The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine.

  2003cited by this paper
• Development of vaccines against meningococcal disease.

  2002cited by this paper
• Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story.

  2001cited by this paper
• Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.

  2001cited by this paper
• Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

  2001cited by this paper
• Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries.

  2000cited by this paper
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children

  2000cited by this paper
• A randomised, double-blind, controlled trial of the immunogenicity and tolerability of a meningococcal group C conjugate vaccine in young British infants.

  2000cited by this paper
• Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions

  1999cited by this paper
• Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.

  1999cited by this paper
• Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group

  1997cited by this paper
• Bacterial meningitis in the United States in 1995. Active Surveillance Team.

  1997cited by this paper
• Standardization and a Multilaboratory Comparison ofNeisseria meningitidisSerogroup A and C Serum Bactericidal Assays

  1997cited by this paper
• Bacterial Meningitis in the United States in 1995

  1997cited by this paper
• Hudson et al.

  1977cited by this paper

• Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs

  2024influential citation
• Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data

  2023cites this paper
• Immunogenicity and seroefficacy of pneumococcal conjugate vaccines - a systematic review and network meta-analysis

  2023cites this paper
• Immunogenicity and Safety of a Novel 13-Valent Pneumococcal Vaccine in Healthy Chinese Infants and Toddlers

  2022influential citation
• Safety of routine childhood vaccine coadministration versus separate vaccination

  2022cites this paper
• Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis.

  2020cites this paper
• Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints

  2018cites this paper
• Pneumococcal Immune Response in Infants Whose Mothers Received Tdap Vaccination During Pregnancy

  2017cites this paper
• Pneumococcal Immune Response in Infants Whose Mothers Received Tetanus, Diphtheria and Acellular Pertussis Vaccination During Pregnancy

  2017cites this paper
• Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects

  2015cites this paper
• Chapter 32 – Vaccines

  2014cites this paper
• Lot-to-lot consistency of live attenuated SA 14-14-2 Japanese encephalitis vaccine manufactured in a good manufacturing practice facility and non-inferiority with respect to an earlier product.

  2014cites this paper
• Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

  2013cites this paper